Lifespan Rhode Island Hospital
Providence, RI
Filters
Save & Share
Clear Filters
Accepting patients
TY-2136b
A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
NCI-COG Pediatric MATCH
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Learn more- ALK Inhibitor
- EphA2 Inhibitor
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials